Booster vaccines dose reduced mortality in hospitalized COVID-19 patients requiring oxygen supplementation: Evidence from the Beijing Omicron outbreak

References

• WHO. Coronavirus dashboard. [Accessed: 2023 Jaly 10]. https://covid19whoint/.
   Google Scholar
• Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis. 2023;23(4):421–7. doi:10.1016/S1473-3099(22)00732-0.
   PubMed Web of Science ®Google Scholar
• Grapsa E, Adamos G, Andrianopoulos I, Tsolaki V, Giannakoulis VG, Karavidas N, Giannopoulou V, Sarri K, Mizi E, Gavrielatou E. Association between vaccination status and mortality among intubated patients with COVID-19–related acute respiratory distress syndrome. JAMA Netw Open. 2022;5(10):e2235219. doi:10.1001/jamanetworkopen.2022.35219.
   PubMed Web of Science ®Google Scholar
• Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, Buckley BS, Probyn K, Villanueva G, Henschke N. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;12(3):Cd015477. doi:10.1002/14651858.CD015477.
   PubMedGoogle Scholar
• Council JPaCMoS. Joint prevention and control mechanism of. State Council Authority publishing; https://www.gov.cn/xinwen/gwylflkjz183/index.htm.
   Google Scholar
• Murphy TJ, Swail H, Jain J, Anderson M, Awadalla P, Behl L, Brown PE, Charlton CL, Colwill K, Drews SJ. The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020–2023. Cmaj. 2023;195(31):1030–7. doi:10.1503/cmaj.230249.
   Web of Science ®Google Scholar
• Islam MA, Shahi S, Marzan AA, Amin MR, Hasan MN, Hoque MN, Ghosh A, Barua A, Khan A, Dhama K. Variant-specific deleterious mutations in the SARS-CoV-2 genome reveal immune responses and potentials for prophylactic vaccine development. Front Pharmacol. 2023;14:1090717. doi:10.3389/fphar.2023.1090717.
   PubMed Web of Science ®Google Scholar
• Miteva D, Kitanova M, Batselova H, Lazova S, Chervenkov L, Peshevska-Sekulovska M, Sekulovski M, Gulinac M, Vasilev GV, Tomov L. The end or a new era of development of SARS-CoV-2 virus: genetic variants responsible for severe COVID-19 and clinical efficacy of the most commonly used vaccines in clinical practice. Vaccines. 2023;11(7):1181. doi:10.3390/vaccines11071181.
   Web of Science ®Google Scholar
• Jamaati H, Karimi S, Ghorbani F, Panahi Y, Hosseini-Baharanchi FS, Hajimoradi M, Malek R, Noorali S, Mokhtari M, Khoundabi B. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: a national cohort study in Iran. J Med Virol. 2023;95(3):e28607. doi:10.1002/jmv.28607.
   PubMed Web of Science ®Google Scholar
• de Freitas Paganoti C, Alkmin da Costa R, da Costa RA, da Silva Costa F, Quintana SM, Graziela de Godoi L, de Freitas Paganoti C, de Godoi LG, Adriana Jiménez Monroy N, Sacramento Rodrigues A. COVID-19 vaccines confer protection in hospitalized pregnant and postpartum women with severe COVID-19: a retrospective cohort study. Vaccines. 2022;10(5):749. doi:10.3390/vaccines10050749.
   Web of Science ®Google Scholar
• Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD, Ho A, Aston S, Wootton DG, Richter A. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Med. 2023;20(1):e1004086. doi:10.1371/journal.pmed.1004086.
   PubMed Web of Science ®Google Scholar
• Huespe IA, Ferraris A, Lalueza A, Valdez PR, Peroni ML, Cayetti LA, Mirofsky MA, Boietti B, Gómez‐Huelgas R, Casas‐Rojo JM. COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: differences between vaccine subtypes. a multicontinental cohort study. J Med Virol. 2023;95(5):e28786. doi:10.1002/jmv.28786.
   PubMed Web of Science ®Google Scholar
• Brosh-Nissimov T, Hussein K, Wiener-Well Y, Orenbuch-Harroch E, Elbaz M, Lipman-Arens S, Maor Y, Yagel Y, Chazan B, Hershman-Sarafov M. Hospitalized patients with severe coronavirus disease 2019 during the Omicron wave in Israel: benefits of a fourth vaccine dose. Clin Infect Dis. 2023;76(3):234–9. doi:10.1093/cid/ciac501.
   Web of Science ®Google Scholar
• Busic N, Lucijanic T, Barsic B, Luksic I, Busic I, Kurdija G, Barbic L, Kunstek S, Jelic T, Lucijanic M. Vaccination provides protection from respiratory deterioration and death among hospitalized COVID-19 patients: differences between vector and mRNA vaccines. J Med Virol. 2022;94(6):2849–54. doi:10.1002/jmv.27666.
   PubMed Web of Science ®Google Scholar
• Bohnert AS, Kumbier K, Rowneki M, Gupta A, Bajema K, Hynes DM, Viglianti E, O’Hare AM, Osborne T, Boyko EJ. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study. BMJ. 2023;381:e074521. doi:10.1136/bmj-2022-074521.
   PubMedGoogle Scholar
• McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, Wu, P, Leung, G.M, Cowling, BJ. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22(10):1435–43. doi:10.1016/S1473-3099(22)00345-0.
   PubMed Web of Science ®Google Scholar
• Xiao J, Cheung JK, Wu P, Ni MY, Cowling BJ, Liao Q. Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: serial cross-sectional surveys. Lancet Reg Health West Pac. 2022;23:100441. doi:10.1016/j.lanwpc.2022.100441.
   PubMedGoogle Scholar
• Ng RWY, Sze RKH, Chong KC, Zhao S, Ling L, Lui G, Leung ASY, Yeung ACM, Ho WCS, Wong MCS. Effectiveness of mRNA and inactivated COVID-19 vaccines: a test-negative study in an infection-naïve Hong Kong population. J Infect. 2023;87(2):136–43. doi:10.1016/j.jinf.2023.05.020.
   PubMed Web of Science ®Google Scholar
• Heidarzadeh A, Amini Moridani M, Khoshmanesh S, Kazemi S, Hajiaghabozorgi M, Karami M. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. Int J Infect Dis. 2023;128:212–22. doi:10.1016/j.ijid.2022.12.024.
   PubMed Web of Science ®Google Scholar
• Wei Y, Jia KM, Zhao S, Hung CT, Mok CKP, Poon PKM, Man Leung EY, Wang MH, Yam CHK, Chow TY. Estimation of vaccine effectiveness of coronaVac and BNT162b2 against severe outcomes over time among patients with SARS-CoV-2 Omicron. JAMA Netw Open. 2023;6(2):e2254777. doi:10.1001/jamanetworkopen.2022.54777.
   PubMed Web of Science ®Google Scholar
• Grima AA, Murison KR, Simmons AE, Tuite AR, Fisman DN. Relative virulence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among vaccinated and unvaccinated individuals hospitalized with SARS-CoV-2. Clin Infect Dis. 2023;76(3):409–15. doi:10.1093/cid/ciac412.
   Google Scholar
• Yan VKC, Wan EYF, Ye X, Mok AHY, Lai FTT, Chui CSL, Li X, Wong CKH, Li PH, Ma T. Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study. Emerg Microbes Infect. 2023;12(1):2209201. doi:10.1080/22221751.2023.2209201.
   PubMed Web of Science ®Google Scholar
• Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4):483–95. doi:10.1016/S1473-3099(21)00681-2.
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMoa2114583.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Kawase J, Hayashi M, Imaizumi K, Ito Y, Okazawa M. COVID-19 symptom-onset to diagnosis and diagnosis to treatment intervals are significant predictors of disease progression and hospitalization in high-risk patients: a real world analysis. Respir Investig. 2023;61(2):220–9. doi:10.1016/j.resinv.2023.01.002.
   PubMed Web of Science ®Google Scholar
• Belayachi J, Obtel M, Mhayi A, Razine R, Abouqal R, Lau EHY. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero cells) against COVID-19 associated severe and critical hospitalization in Morocco. PLOS ONE. 2022;17(12):e0278546. doi:10.1371/journal.pone.0278546.
   PubMed Web of Science ®Google Scholar
• Jin L, Li Z, Zhang X, Li J, Zhu F. CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Hum Vaccin Immunother. 2022;18(6):2096970. doi:10.1080/21645515.2022.2096970.
   PubMed Web of Science ®Google Scholar
• Arbel R, Sergienko R, Friger M, Peretz A, Beckenstein T, Yaron S, Netzer D, Hammerman A. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med. 2022;28(7):1486–90. doi:10.1038/s41591-022-01832-0.
   PubMed Web of Science ®Google Scholar